fashion -WSS

fashion

author：leisure time 2025-10-02 19:39:04 - browse：2484

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Medicare has officially expanded its coverage policy for brain scans that detect a brain plaque associated with Alzheimer’s disease, the agency announced on Friday.

Amyloid PET scans are important tools to help determine whether patients with mild cognitive impairment are good candidates for new Alzheimer’s drugs, including Eisai and Biogen’s drug Leqembi, which means there will likely be an increase in demand for the scans as uptake increases.

Previously, Medicare limited coverage for the drug to patients enrolled in clinical studies, and only covered one scan in a patient’s lifetime. The new coverage policy removes those restrictions and delegates decisions about how many scans to cover to regional Medicare administrators.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： To avoid data mishandling cases, universities eye AI and other tools

WSS

STAT Summit: Ending the crisis of Black deaths in the U.S.

Health tech investors get more selective as pandemic boom fades

PhRMA lawsuit over Medicare drug price negotiation tossed

Medical mystery: When a cough is not just a cough

J&J lung cancer data amount to new salvo against AstraZeneca

For Medicare Advantage, Democrats want stronger protections around AI

hotspot

fashion

entertainment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Vaccine advisory panel ACIP left half staffed by HHS

As demand for Covid shots wanes, Moderna seeks its next success

KalVista pill reduced swelling 'attacks' caused by genetic disease

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA clears Verve to begin U.S. study of gene

FDA approval of Sarepta Duchenne genetic therapy gives me hope

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

At least 13 dead in Texas as scorching temps continue

Readout LOUD podcast: Live from the 2023 STAT Summit

Wikipedia

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Study on Amgen’s bispecific immunotherapy produces positive data

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Private equity deals in Medicare Advantage declines

Gilead might be held responsible for not developing a drug

The dental labor crisis is a moment of opportunity

focus

hotspot

Wikipedia

focus